|

SHR-A2102 Clinical Trials

11 actively recruiting trials

▲ +1 trial since June 2026

Pipeline

Phase 1: 1Phase 2: 6Phase 1/2: 4

Top Sponsors

  • Shanghai Hengrui Pharmaceutical Co., Ltd.6
  • Fudan University3
  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
  • Beijing GoBroad Hospital1

Indications

  • Cancer11
  • Breast Cancer4
  • Advanced Breast Cancer3
  • Advanced Solid Tumors3
  • HER2-negative Breast Cancer2

Other11 trials

A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 1/2
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Phase 2
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
Phase 1/2
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
Phase 1/2
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Phase 2
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
Phase 1/2
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
Phase 1
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Phase 2
Reverse Triple Negative Immune Resistant Breast Cancer
Phase 2
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Phase 2
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.